World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
43139
World Ranking
14372
National Ranking
7266

Amita Patnaik publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Amita Patnaik sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 531 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Amita Patnaik D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Amita Patnaik sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Amita Patnaik is affiliated with the University of Chicago in the United States and has a substantial body of research primarily within the field of Medicine. Their work focuses notably on oncology and related subfields, with 141 publications in Oncology, 51 in Pulmonary and Respiratory Medicine, 33 in Radiology, Nuclear Medicine and Imaging, 31 in Molecular Biology, and 30 in Immunology.

The scientist's research has concentrated on several major topics including Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Lung Cancer Treatments and Mutations, and Colorectal Cancer Treatments and Studies.

Frequent publication venues for Amita Patnaik include the Journal of Clinical Oncology with 38 publications, Cancer Research with 33, Regular and Young Investigator Award Abstracts with 13, Annals of Oncology with 12, and Clinical Cancer Research with 7.

Their recent published papers reflect topics on cancer therapy and treatment strategies across multiple tumor types:

  • Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC (2020), Journal of Thoracic Oncology
  • Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study (2022), The Lancet Oncology
  • Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody (2021), Clinical Cancer Research
  • Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial (2023), Clinical Cancer Research
  • The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads (2020), American Society of Clinical Oncology Educational Book

Amita Patnaik has collaborated extensively with a number of researchers. Frequent co-authors include Kyriakos P. Papadopoulos, Drew Rasco, Nehal J. Lakhani, Alyssa Simonson, and Manish Sharma, reflecting ongoing partnerships in clinical and translational oncology research.

Best Publications

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

    O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

    Timothy A. Yap;Li Yan;Amita Patnaik;Ivy Fearen

  • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

    F. Stephen Hodi;Wen Jen Hwu;Richard Kefford;Jeffrey S. Weber

  • Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos

  • Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Adil I. Daud;Jedd D. Wolchok;Caroline Robert;Wen Jen Hwu

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer

    Toshio Shimizu;Anthony W. Tolcher;Kyriakos P. Papadopoulos;Muralidhar Beeram

  • First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

    Branimir I. Sikic;Nehal Lakhani;Amita Patnaik;Sumit A. Shah

  • Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

    Caroline Robert;Caroline Robert;Antoni Ribas;Omid Hamid;Adil Daud

  • Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

    Alain C. Mita;Louis J. Denis;Eric K. Rowinsky;Johann S. DeBono

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

    A W Tolcher;S L Gerson;L Denis;C Geyer

  • Raf: A Strategic Target for Therapeutic Development Against Cancer

    Muralidhar Beeram;Amita Patnaik;Eric K. Rowinsky

Frequent Co-Authors

Anthony W. Tolcher
Anthony W. Tolcher Texas Oncology
Richard F. Kefford
Richard F. Kefford Macquarie University
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Adil Daud
Adil Daud University of California, San Francisco
Caroline Robert
Caroline Robert University of Paris-Saclay
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Patricia LoRusso
Patricia LoRusso Yale University
Peter Hersey
Peter Hersey University of Sydney
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying medicine in the USA, you may also want to explore alternative healthcare career options and flexible learning paths. Many students are turning to accelerated programs, such as direct entry msn programs online, which allow non-nurses to earn a master’s in nursing and start a new career quickly.

For those seeking less competitive admission processes, you can find easiest nursing programs to get into, offering accessible options for prospective students who may not meet stringent entrance requirements.

Not everyone wants a direct patient care role—medical billing and coding is a fast-growing field with many online study choices. There are accredited medical billing and coding schools with financial aid to help you launch your career without overwhelming costs.

Finally, test requirements can be a barrier. Some nursing schools that don't require teas or hesi exams offer a streamlined path for students who are ready to take the next step but want to avoid additional standardized testing.

Best Scientists Citing Amita Patnaik

Trending Scientists

Recently Published Articles